BRIDGEWATER, N.J., Feb. 26 /PRNewswire-FirstCall/ -- Sanofi-aventis announced today that the U.S. Food and Drug Administration (FDA) approved Apidra(R) SoloSTAR(R ...
Tresiba and Lantus are both long-acting insulins used to manage blood sugar levels in people with type 1 or type 2 diabetes. (For more information on each’s drug uses, see the “What are Tresiba and ...
Sanofi has put off a biosimilar threat to Lantus till the end of 2016. In a patent settlement announced on Monday, the French drugmaker and U.S.-based Eli Lilly & Co. agreed to a royalty deal covering ...
HERTFORDSHIRE, England and PITTSBURGH, May 29, 2020 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) today announced that the U.S. Patent and Trademark Appeal Board (PTAB) has ruled in favor of Mylan in inter ...
The information provided on this page is intended to serve as a comprehensive resource and should not be a substitute to professional medical advice. If you have concerns it is always best to speak ...
Paris, France - September 28, 2015 - Sanofi announced today that it has reached a settlement agreement with Eli Lilly and Company ("Lilly"), which addresses patents on Sanofi's Lantus® SoloSTAR® ...
As with other drugs, Lantus (insulin glargine) can cause side effects, such as weight gain and injection site reactions. If side effects of Lantus become difficult to tolerate, talk with your doctor ...
Lantus (insulin glargine) is a brand-name subcutaneous injection that’s prescribed for diabetes. It’s used in adults and some children. The cost of the drug with and without insurance can depend on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results